MIGUEL ÁNGEL
CALLEJA HERNÁNDEZ
Investigador en el periodo 2016-2017
Publicaciones en las que colabora con MIGUEL ÁNGEL CALLEJA HERNÁNDEZ (28)
2021
-
Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis
Molecular Neurobiology, Vol. 58, Núm. 9, pp. 4716-4726
2020
-
Association of ABCB1 and VEGFA gene polymorphisms with breast cancer susceptibility and prognosis
Pathology Research and Practice, Vol. 216, Núm. 4
2019
-
Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients
Pharmacogenomics Journal, Vol. 19, Núm. 2, pp. 164-177
2018
-
Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer
Pathology Research and Practice, Vol. 214, Núm. 1, pp. 44-52
-
Pharmacogenetic biomarkers of response in Crohn's disease
Pharmacogenomics Journal, Vol. 18, Núm. 1, pp. 1-13
2017
-
ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis
Surgical Oncology, Vol. 26, Núm. 4, pp. 473-482
-
Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
Mutation Research - Reviews in Mutation Research, Vol. 771, pp. 32-58
-
Cytokine single-nucleotide polymorphisms and risk of non-small-cell lung cancer
Pharmacogenetics and Genomics, Vol. 27, Núm. 12, pp. 438-444
-
Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer
Surgical Oncology, Vol. 26, Núm. 3, pp. 278-285
2016
-
ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients
Pharmacological Research, Vol. 108, pp. 111-118
-
Gene polymorphisms as predictors of response to biological therapies in psoriasis patients
Pharmacological Research, Vol. 113, pp. 71-80
-
Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis
Pharmacological Research, Vol. 111, pp. 264-271
-
Liquid biopsy in early stage lung cancer
Translational Lung Cancer Research, Vol. 5, Núm. 5, pp. 517-524
-
Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients
Pharmacological Research, Vol. 111, pp. 877-884
-
Relevance of BRAF and NRAS mutations in the primary tumor and metastases of papillary thyroid carcinomas
Head and Neck, Vol. 38, Núm. 12, pp. 1772-1779
2015
-
De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer
Pharmacogenomics, Vol. 16, Núm. 12, pp. 1411-1426
-
Extrapolation of acenocoumarol pharmacogenetic algorithms
Vascular Pharmacology, Vol. 74, pp. 151-157
-
MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer
Pharmacological Research, Vol. 102, pp. 90-106
-
MET: A new promising biomarker in non-small-cell lung carcinoma
Pharmacogenomics, Vol. 16, Núm. 6, pp. 631-647
-
Molecular biomarkers in colorectal carcinoma
Pharmacogenomics, Vol. 16, Núm. 10, pp. 1189-1222